Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 7/20 | 0.57 |
| ▸ | TGFBR1 | P36897 | 7/20 | 0.50 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23872945 | 0.89 | TGFBR1 (0.50) | CLK1TGFBR1EPHB3MAP3K5 | |
| SCHEMBL18069378 | 0.84 | PIK3CA (0.41) | CLK1TGFBR1EPHB3MAP3K5 | |
| SCHEMBL22939908 | 0.84 | TGFBR1 (0.47) | CLK1TGFBR1EPHB3 | |
| SCHEMBL22955473 | 0.83 | TGFBR1 (0.54) | CLK1TGFBR1 | |
| SCHEMBL15829438 | 0.82 | TGFBR1 (0.48) | TGFBR1 | |
| SCHEMBL26353091 | 0.82 | CLK1 (0.41) | CLK1TGFBR1EPHB3MAP3K5 | |
| SCHEMBL26352031 | 0.81 | CLK1 (0.42) | CLK1TGFBR1 | |
| SCHEMBL14145741 | 0.81 | CLK1 (0.61) | CLK1TGFBR1EPHB3 | |
| SCHEMBL22939904 | 0.80 | TGFBR1 (0.50) | CLK1TGFBR1EPHB3EPHX2NR1H4 | |
| SCHEMBL26351993 | 0.80 | CLK1 (0.57) | CLK1TGFBR1EPHB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2023-02-21 | — | — | US | disclosed |
| US-11466003-B2 | Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2022-10-11 | — | — | US | disclosed |
| US-20210300916-A1 | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-09-30 | — | — | US | disclosed |
| US-20210032241-A1 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303562-A1 | PYRAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, CYP4F11, WEE1 | CLK1 4184/4885TGFBR1 1681/4885EPHB3 4801/4885 |
| US-20210032241-A1 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, NOTUM, WEE1 | CLK1 4460/4885TGFBR1 186/4885EPHB3 4194/4885 |
| US-11466003-B2 | Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof | NOTUM, ALKBH5, PAH | CLK1 4691/4885TGFBR1 613/4885EPHB3 4559/4885 |
| US-20210300916-A1 | NITROGENOUS HETEROCYCLIC AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION THEREOF | NOTUM, ALKBH5, PAH | CLK1 4691/4885TGFBR1 613/4885EPHB3 4559/4885 |
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | ALK, NOTUM, WEE1 | CLK1 4460/4885TGFBR1 186/4885EPHB3 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.